Premium
Cyclic Depsipeptide BE‐43547A 2 : Synthesis and Activity against Pancreatic Cancer Stem Cells
Author(s) -
Sun Yuanjun,
Ding Yahui,
Li Dongmei,
Zhou Ruifei,
Su Xiuwen,
Yang Juan,
Guo Xiaoqian,
Chong Chuanke,
Wang Jinghan,
Zhang Weicheng,
Bai Cuigai,
Wang Liang,
Chen Yue
Publication year - 2017
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201709744
Subject(s) - depsipeptide , cancer stem cell , stem cell , pancreatic cancer , cancer research , in vivo , chemistry , cancer cell , carcinogenesis , hydroxylation , cancer , biochemistry , biology , microbiology and biotechnology , genetics , enzyme , gene
Asymmetric total synthesis of the cyclic depsipeptide BE‐43547A 2 was achieved in 15 linear steps on a 350 mg scale in one batch. The synthesis features the highly diastereoselective construction of an α‐hydroxy‐β‐ketoamide through α‐hydroxylation with a d.r. of up to 86:1. BE‐43547A 2 significantly reduces the percentage of pancreatic cancer stem cells (PCSCs) in Panc‐1 cell cultures, and dramatically reduces the tumorsphere‐forming capability of Panc‐1 cells. An in vivo tumor‐initiation assay, a gold standard for cancer stem cell assays, confirmed that BE‐43547A 2 can abolish the tumorigenesis of Panc‐1 cells. The anti‐PCSC activity of BE‐43547A 2 could make this depsipeptide scaffold a promising starting point for discovering new PCSC‐targeting drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom